ACTU
ACTU
Last
$0.61
Day
-10.1%
1y
-91.6%
5y
-92.1%
52w
-92.0%
SPY YTD
+13.3%
Sec
—
Earnings
2026-11-1232d
EMA 21
0.86
EMA 50
1.08
EMA 200
2.62
20d high
-37.7%
5y high
-94.3%
5y range
1th
Positions held
Your positionsACTU isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$0.92
Stop
$0.48
Stop distance
21.3%
Target vs last
+50.8%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
Headline scan
Headlines — positive tone
• [OK · fundamentals] All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy
News
2026-10-08 · AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
2026-10-07 · Top Premarket Decliners
2026-09-09 · Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 · All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy
Price (daily)
Full chart · RSI · MACD · patternsACTU · daily-25.2% over 14 sessions
Close EMA21 EMA50 EMA200